Trials / Completed
CompletedNCT02656498
[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
An Open Label, Multicenter Study for Evaluation of the Clinical Utility of [18F]THK-5351 Positron Emission Computed Tomography in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, Subjects With Alzheimer's Disease and Subjects With Other Neurodegenerative Diseases
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Jae Seung Kim · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This is a cross-sectional and longitudinal study to evaluate the clinical utility of \[18F\]THK-5351 positron emission computed tomography in cognitively healthy volunteers, mild cognitive impairment (MCI), Alzheimer's disease (AD) and other neurodegenerative patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]THK-5351 | Imaging for evaluating the accumulation of abnormal tau protein in the brain |
Timeline
- Start date
- 2016-01-11
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
- First posted
- 2016-01-15
- Last updated
- 2020-12-14
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02656498. Inclusion in this directory is not an endorsement.